Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGM NASDAQ:DRCT NASDAQ:SLGL NASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$0.37-1.4%$0.33$0.26▼$11.80$35.97M1.81289,954 shs53,203 shsDRCTDirect Digital$2.71+2.5%$3.22$2.17▼$172.70$1.99M5.34444,909 shs9,872 shsSLGLSol-Gel Technologies$74.76+0.5%$72.77$6.96▼$97.97$210.82M1.1334,525 shs8,916 shsTRAWTraws Pharma$0.82+0.3%$1.34$0.64▼$3.27$8.36M1.451.29 million shs98,042 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+16.09%+13.05%+18.25%+24.00%-96.87%DRCTDirect Digital-0.38%-5.04%-6.71%-18.52%-97.78%SLGLSol-Gel Technologies+1.24%+0.83%+0.74%-6.07%+916.53%TRAWTraws Pharma-0.76%-7.97%-43.79%-55.15%-42.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$0.37-1.4%$0.33$0.26▼$11.80$35.97M1.81289,954 shs53,203 shsDRCTDirect Digital$2.71+2.5%$3.22$2.17▼$172.70$1.99M5.34444,909 shs9,872 shsSLGLSol-Gel Technologies$74.76+0.5%$72.77$6.96▼$97.97$210.82M1.1334,525 shs8,916 shsTRAWTraws Pharma$0.82+0.3%$1.34$0.64▼$3.27$8.36M1.451.29 million shs98,042 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+16.09%+13.05%+18.25%+24.00%-96.87%DRCTDirect Digital-0.38%-5.04%-6.71%-18.52%-97.78%SLGLSol-Gel Technologies+1.24%+0.83%+0.74%-6.07%+916.53%TRAWTraws Pharma-0.76%-7.97%-43.79%-55.15%-42.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMBGM Group 1.00SellN/AN/ADRCTDirect Digital 1.50ReduceN/AN/ASLGLSol-Gel Technologies 2.67Moderate Buy$197.50164.19% UpsideTRAWTraws Pharma 1.60Reduce$1.0021.51% UpsideCurrent Analyst Ratings BreakdownLatest TRAW, DRCT, SLGL, and BGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026SLGLSol-Gel Technologies MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$285.006/18/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Negative$1.006/18/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$1.006/15/2026TRAWTraws Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral6/15/2026TRAWTraws Pharma LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/4/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D-)5/29/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (E+)5/29/2026SLGLSol-Gel Technologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/22/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D+)5/20/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/15/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMBGM Group$26.85M1.34N/AN/A$7.34 per share0.05DRCTDirect Digital$34.69M0.06N/AN/A($18.82) per share-0.14SLGLSol-Gel Technologies$19.39M10.83N/AN/A$8.19 per share9.13TRAWTraws Pharma$2.79M3.00$0.76 per share1.08($0.07) per share-11.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMBGM Group-$1.44MN/AN/AN/AN/AN/AN/AN/AN/ADRCTDirect Digital-$18.95M-$201.62N/AN/AN/A-65.75%N/A-59.57%8/4/2026 (Estimated)SLGLSol-Gel Technologies-$6.13M-$0.34N/AN/AN/A-5.66%-3.17%-2.58%8/21/2026 (Estimated)TRAWTraws Pharma$9.17M-$1.69N/AN/AN/AN/A-913.18%-133.88%8/13/2026 (Estimated)Latest TRAW, DRCT, SLGL, and BGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q1 2026SLGLSol-Gel Technologies-$2.86-$1.31+$1.55$1.31$0.90 million$0.11 million5/15/2026Q4 2025TRAWTraws Pharma-$0.92-$0.53+$0.39-$0.53$2.72 millionN/A5/11/2026Q4 2025DRCTDirect Digital-$7.74-$7.25+$0.49-$10.32$6.82 million$6.68 million4/15/2026Q4 2025TRAWTraws Pharma-$1.2238-$0.71+$0.5138-$0.71$0.06 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBGMBGM GroupN/AN/AN/AN/AN/ADRCTDirect DigitalN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMBGM GroupN/AN/AN/ADRCTDirect DigitalN/A0.160.16SLGLSol-Gel TechnologiesN/A8.848.84TRAWTraws PharmaN/A0.430.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMBGM GroupN/ADRCTDirect Digital4.02%SLGLSol-Gel Technologies26.18%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipBGMBGM Group58.66%DRCTDirect Digital25.57%SLGLSol-Gel Technologies66.51%TRAWTraws Pharma7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMBGM Group29897.22 million40.19 millionN/ADRCTDirect Digital60740,000553,000Not OptionableSLGLSol-Gel Technologies502.81 million941,000No DataTRAWTraws Pharma1710.16 million9.39 millionNo DataTRAW, DRCT, SLGL, and BGM HeadlinesRecent News About These CompaniesTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramJune 22, 2026 | globenewswire.comQ2 EPS Estimates for Traws Pharma Lifted by HC WainwrightJune 22, 2026 | americanbankingnews.comBrokerages Set Traws Pharma, Inc. (NASDAQ:TRAW) Target Price at $8.00June 20, 2026 | americanbankingnews.comOutlook for Bucks County biotech take another hit with second setback for flu drugJune 15, 2026 | bizjournals.comTraws defers midphase flu study after negative regulatory reviewJune 15, 2026 | fiercebiotech.comFMicron, Nebius surge premarket; Traws Pharma tumblesJune 15, 2026 | finance.yahoo.comTraws Pharma shares slide after UK regulator postpones influenza studyJune 15, 2026 | msn.comWhy did TRAW stock slump 28% after hours?June 13, 2026 | msn.comTraws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory ReviewJune 12, 2026 | quiverquant.comQTraws Pharma Provides Regulatory Update on Influenza ProgramJune 12, 2026 | globenewswire.comTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease OutbreaksMay 27, 2026 | globenewswire.comTraws Pharma Updates ATM Equity Offering Prospectus SupplementsMay 26, 2026 | tipranks.comTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsMay 15, 2026 | globenewswire.comTraws Pops on Hantavirus ResearchMay 9, 2026 | baystreet.caA hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gainsMay 9, 2026 | msn.comTraws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship OutbreakMay 8, 2026 | benzinga.comTraws Pharma Advances Development of Clinical Candidates for Hantavirus TreatmentMay 8, 2026 | quiverquant.comQTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsMay 8, 2026 | globenewswire.comTraws Pharma (TRAW) price target decreased by 24.14% to 5.61April 29, 2026 | msn.comTraws Pharma (NASDAQ:TRAW) Major Shareholder Purchases $998,207.43 in StockApril 29, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRAW, DRCT, SLGL, and BGM Company DescriptionsBGM Group NASDAQ:BGM$0.37 -0.01 (-1.36%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Direct Digital NASDAQ:DRCT$2.70 +0.07 (+2.46%) As of 01:55 PM Eastern This is a fair market value price provided by Massive. Learn more.Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.Sol-Gel Technologies NASDAQ:SLGL$74.76 +0.35 (+0.47%) As of 01:55 PM Eastern This is a fair market value price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Traws Pharma NASDAQ:TRAW$0.82 +0.00 (+0.28%) As of 01:54 PM Eastern This is a fair market value price provided by Massive. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Wall Street Still Sees Massive Upside for AeroVironment Stock Manchester United’s Stock Rally Faces a Test Beyond Old Trafford Why AppLovin’s CEO Is Selling While Quantum Insiders Are Buying Volkswagen’s 16-Year Low Masks a Massive Margin Engine Palantir’s Rough 2026 Start Raises a Bigger Question About Its AI Moat Overclocking Qualcomm: Rewiring the AI Compute Market SpaceX Achieves Escape Velocity With Nasdaq Fast-Track 3 Top Financial Institutions Announce Over $70 Billion in Share Repurchases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
